CFTR and cystic fibrosis: While data specifically focusing on CF-ABPA patients are limited, findings from epidemiologic and retrospective studies suggest the potential for CFTR modulator therapies to positively influence pulmonary outcomes in this population as well [12,31,32,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107].